SARC’s resources include access to the SARC Biospecimen Bank, SARC Clinical Data Repository, SARC Imaging Resources, and additional resources including the sarcoma drug response portal. We help multi-institutional research happen. Our aim is to be the catalyst for true translational research, ensuring that bench-to-bedside studies are translated to treatments or therapies for medical practice.
SARC Biospecimen Bank
The SARC Biospecimen Bank is designed to help qualified sarcoma investigators or organizations gain access to de-identified specimens to carry out projects that may explore relevant biomarkers, identify novel therapeutic targets, or make other translational discoveries. The SARC Development Therapeutics Committee (DTC) invites applications to conduct translational research using these materials.
Learn more about the SARC Biospecimen Bank.
SARC Clinical Data Repository
SARC has established a repository of clinical data sets from 12 clinical trials, including more than 1,700 patients.
Learn more about SARC Clinical Data Repository.
SARC Imaging Resources
SARC imaging data collected from two clinical trials is now available to sarcoma researchers for further query.
Learn more about SARC Imaging Resources.
SARC Genomic Portal
To help provide our research community with more direct access to genomic data sets onsarcomas, SARC has provided funds from the Development Therapeutics Committee(DTC)to engage the Translational Genomics Research Institute (TGen) to build and maintain an accessible, user-friendly genomic portal.
The SARC Genomic Portal will be available in 2018.
We foster collaboration among investigators, academia, and pharma. The National Cancer Institute (NCI) agent formulary (NCI Formulary) is a public-private partnership between the NCI and pharmaceutical and biotechnology companies with a purpose of providing academic investigators with rapid access to agents or combinations of agents for cancer clinical trial use. Agents within the NCI Formulary are available to investigators at NCI-designated Cancer Centers for the conduct of clinical trials under investigator-held IND, as well as pre-clinical research.
Visit the NCI Formulary website to review the list of available agents
Sarcoma Drug Response Portal
The National Cancer Institute performed a screen of 100 FDA-approved compounds and 345 investigational agents in 63 human and pediatric sarcoma cell lines. Gene expression and miRNA expression is also available.
See results published at NCBI.
See data publicly available.